On October 11, 2019, the U.S. Congressional Budget Office (CBO) sent a letter to Representative Frank Pallone Jr., Chairman of the Committee on Energy and Commerce, describing a preliminary estimate of the effects of Title I of H.R. 3 bill.… Continue Reading
The following records were provided by KEI from UCLA on September 28, 2018, following a freedom of Records Request. This page describes the contents of on very large PDF file, the “Combined IN Writ Petition DHC,” which is 1,309 pages long,… Continue Reading
This is the statement the United States of America delivered on behalf of the US government at the WIPO General Assembly, on the work program for the Standing Committee on Copyright and Related Rights (SCCR). The most detailed discussion concerned… Continue Reading
The UK Labour Party Document, “Medicines-For-The-Many” is 52 pages long, including 9 pages of end notes. It is an ambitious document. The document discusses, in some detail, innovation as well as access and affordability. The reforms proposed include measures that… Continue Reading
UPDATE: On 29 July 2019, the co-facilitators (Ambassadors of Georgia and Thailand) of the intergovernmental consultations on a UN political declaration on universal health coverage announced that the silence procedure was broken by “several delegations on paragraphs 29, 68, 69,… Continue Reading
On Thursday, 11 July 2019, the 41st session of the Human Rights Council (HRC) adopted, without a vote, resolution A/HRC/41/L.13, “Access to medicines and vaccines in the context of the right of the highest attainable standard of physical and mental… Continue Reading
(UPDATE: The NIH provided a response to our comments on July 11, 2019) On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063, on the “Prospective Grant of an Exclusive Patent License: Development… Continue Reading
UPDATE: On 4 July 2019, the Core Group will submit a “TABLING REV 1” version of their resolution on “Access to medicines and vaccines in the context of the right of everyone to the enjoyment of the highest attainable standard… Continue Reading
Today the World Health Assembly (WHA) approved A72/A/CONF./2 Rev.1 as a resolution, titled “Improving the transparency of markets for medicines, vaccines, and other health products.” Link to the resolution: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf When the text was made available, I sent out a… Continue Reading
One of the reasons why drug companies have fought so hard to block transparency of clinical trial costs is the growing gap between what the public had been told those costs are, and the actual costs, particularly for treatments for… Continue Reading